US2003171287A1PendingUtilityA1

Medicinal compositions for angiogenic therapy

45
Priority: Jun 27, 2000Filed: Jun 27, 2001Published: Sep 11, 2003
Est. expiryJun 27, 2020(expired)· nominal 20-yr term from priority
Inventors:Ryuichi MorishitaHiromi KoikeTadashi TanabeMotokuni Aoki
A61K 31/5585A61K 31/711A61K 48/00A61P 9/10A61K 38/1858A61K 38/1709A61K 38/52A61K 38/1833A61P 9/00
45
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides: (1) pharmaceutical compositions for angiogenic therapy which contain, as the active ingredients, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor; (2) agents for potentiating the angiogenic effect of a gene encoding an angiogenesis factor that contain, as the active ingredient, at least one substance selected from substances having vasodilating effect and/or platelet aggregation inhibitory effect and substances producing them; (3) an angiogenic agent which contains a prostacyclin synthase gene as the active ingredient; (4) pharmaceutical compositions for angiogenic therapy which contain ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients; (4) an agent which contain ets 1 gene as the active ingredient for potentiating the angiogenic effect of another gene encoding an angiogenesis factor; and (5) an angiogenic agent which contains ets-1 gene as the active ingredient.

Claims

exact text as granted — not AI-modified
1 . A pharmaceutical composition for angiogenic therapy which contains, as the active ingredients, at least one substance selected from the group of: substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them; and a gene encoding an angiogenesis factor.  
     
     
         2 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of a gene encoding an angiogenesis factor with at least one substance selected from the group of: substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them.  
     
     
         3 . The pharmaceutical composition for angiogenic therapy of  claim 1  or  2 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         4 . The pharmaceutical composition for angiogenic therapy of any one of  claims 1  to  3 , wherein the substance producing a substance having vasodilating effect and/or platelet aggregation inhibitory effect is in the form of a gene.  
     
     
         5 . The pharmaceutical composition for angiogenic therapy of  claim 4 , wherein the gene is prostacyclin synthase gene.  
     
     
         6 . A pharmaceutical composition for angiogenic therapy which contains HGF gene and prostacyclin synthase gene as the active ingredients.  
     
     
         7 . A pharmaceutical composition for angiogenic therapy which is characterized by the combined use of HGF gene and prostacyclin synthase gene.  
     
     
         8 . A pharmaceutical composition for angiogenic therapy which contains VEGF gene and prostacylin synthase gene as the active ingredients.  
     
     
         9 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of VEGF gene and prostacyclin synthase gene.  
     
     
         10 . The pharmaceutical composition for angiogenic therapy of any one of  claims 1  to  9 , wherein the composition is used for treating or preventing ischemic disease or arterial disease.  
     
     
         11 . The pharmaceutical composition for angiogenic therapy of  claim 10 , wherein the ischemic disease or arterial disease is selected from the group of arteriosclerosis obliterans, myocardial infarction, angina pectoris, cardiomyopathy, and cerebrovascular disease.  
     
     
         12 . The pharmaceutical composition for angiogenic therapy of any one of  claims 1  to  11 , wherein the gene is introduced in the form of naked DNA.  
     
     
         13 . An agent for potentiating the angiogenic effect due to a gene encoding an angiogenesis factor which contains, as the active ingredient, at least one substance selected from the group of: substances having vasodilating effect and/or platelet aggregation inhibitory effect, and substances producing them.  
     
     
         14 . The agent for potentiating the angiogenic effect of  claim 13 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         15 . The agent for potentiating the angiogenic effect of  claim 13  or  14 , which contains prostacyclin synthase gene as the active ingredient.  
     
     
         16 . An agent for potentiating the angiogenic effect due to HGF gene which contains prostacyclin synthase gene as the active ingredient.  
     
     
         17 . The agent for potentiating the angiogenic effect of any one of  claims 13  to  16 , wherein the agent is used for treating or preventing ischemic disease or arterial disease.  
     
     
         18 . An angiogenic agent which contains prostacyclin synthase gene as the active ingredient.  
     
     
         19 . The angiogenic agent of  claim 18 , wherein the agent is used for treating or preventing ischemic disease or arterial disease.  
     
     
         20 . A pharmaceutical composition for angiogenic therapy which contains ets-1 gene and another gene encoding an angiogenesis factor as the active ingredients.  
     
     
         21 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of ets-1 gene and another gene encoding an angiogenesis factor.  
     
     
         22 . The pharmaceutical composition for angiogenic therapy of  claim 20  or  21 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         23 . A pharmaceutical composition for angiogenic therapy which contains HGF gene and ets-1 gene as the active ingredients.  
     
     
         24 . A pharmaceutical composition for angiogenic therapy, which is characterized by the combined use of HGF gene and ets-1 gene.  
     
     
         25 . The pharmaceutical composition for angiogenic therapy of any one of  claims 20  to  24 , wherein the composition is used for treating or preventing ischemic disease or arterial disease.  
     
     
         26 . An agent containing ets-1 gene as the active ingredient that potentiates the angiogenic effect due to another gene encoding an angiogenesis factor.  
     
     
         27 . The agent for potentiating the angiogenic effect of  claim 26 , wherein the angiogenesis factor is HGF and/or VEGF.  
     
     
         28 . An agent for potentiating the angiogenic effect due to HGF gene, which contains ets-1 gene as the active ingredient.  
     
     
         29 . The agent for potentiating the angiogenic effect of any one of claims  26 . to  28 , wherein the agent is used for treating or preventing ischemic disease or arterial disease.  
     
     
         30 . An angiogenic agent which contains ets-1 gene as the active ingredient.  
     
     
         31 . The angiogenic agent of  claim 30  which is used for treating or preventing ischemic disease or arterial disease.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.